Last reviewed · How we verify
Cyclosporione A withdrawal
Cyclosporine A withdrawal refers to the clinical management of discontinuing cyclosporine A therapy, which involves tapering an immunosuppressant that inhibits calcineurin and T-cell activation.
Cyclosporine A withdrawal refers to the clinical management of discontinuing cyclosporine A therapy, which involves tapering an immunosuppressant that inhibits calcineurin and T-cell activation. Used for Management protocol for discontinuation of cyclosporine A in transplant recipients, Management protocol for discontinuation of cyclosporine A in autoimmune disease patients.
At a glance
| Generic name | Cyclosporione A withdrawal |
|---|---|
| Sponsor | University of Oslo School of Pharmacy |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
This is not a drug itself but rather a clinical protocol for safely discontinuing cyclosporine A, an established immunosuppressant used in transplantation and autoimmune conditions. The withdrawal process requires careful monitoring to prevent rejection episodes or disease flares. Cyclosporine A normally works by blocking calcineurin-dependent T-cell proliferation; withdrawal necessitates gradual dose reduction and close clinical surveillance.
Approved indications
- Management protocol for discontinuation of cyclosporine A in transplant recipients
- Management protocol for discontinuation of cyclosporine A in autoimmune disease patients
Common side effects
- Organ rejection (in transplant patients)
- Disease flare or relapse (in autoimmune conditions)
- Rebound inflammation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclosporione A withdrawal CI brief — competitive landscape report
- Cyclosporione A withdrawal updates RSS · CI watch RSS
- University of Oslo School of Pharmacy portfolio CI